199 related articles for article (PubMed ID: 37620288)
1. Using prostate-specific membrane antigen positron-emission tomography to guide prostate biopsies and stage men at high-risk of prostate cancer.
Bodar YJL; Boevé LMS; van Leeuwen PJ; Baars PC; Nieuwenhuijzen JA; van Haarst EP; Oddens JR; Donswijk ML; van Riel LAMJG; Scheltema MJ; Meijer D; Hendrikse NH; Oprea-Lager DE; Vis AN
BJU Int; 2023 Dec; 132(6):705-712. PubMed ID: 37620288
[TBL] [Abstract][Full Text] [Related]
2. The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study.
Emmett L; Buteau J; Papa N; Moon D; Thompson J; Roberts MJ; Rasiah K; Pattison DA; Yaxley J; Thomas P; Hutton AC; Agrawal S; Amin A; Blazevski A; Chalasani V; Ho B; Nguyen A; Liu V; Lee J; Sheehan-Dare G; Kooner R; Coughlin G; Chan L; Cusick T; Namdarian B; Kapoor J; Alghazo O; Woo HH; Lawrentschuk N; Murphy D; Hofman MS; Stricker P
Eur Urol; 2021 Dec; 80(6):682-689. PubMed ID: 34465492
[TBL] [Abstract][Full Text] [Related]
3. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer.
Amin A; Blazevski A; Thompson J; Scheltema MJ; Hofman MS; Murphy D; Lawrentschuk N; Sathianathen N; Kapoor J; Woo HH; Chalasani V; Rasiah K; van Leeuwen PJ; Tang R; Cusick T; Stricker P; Emmett L
BJU Int; 2020 Apr; 125(4):515-524. PubMed ID: 31957122
[TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
5. Risk of metastatic disease on
Yaxley JW; Raveenthiran S; Nouhaud FX; Samaratunga H; Yaxley WJ; Coughlin G; Yaxley AJ; Gianduzzo T; Kua B; McEwan L; Wong D
BJU Int; 2019 Sep; 124(3):401-407. PubMed ID: 31141284
[TBL] [Abstract][Full Text] [Related]
6. Detection of prostate cancer with
Bodar YJL; Jansen BHE; van der Voorn JP; Zwezerijnen GJC; Meijer D; Nieuwenhuijzen JA; Boellaard R; Hendrikse NH; Hoekstra OS; van Moorselaar RJA; Oprea-Lager DE; Vis AN
World J Urol; 2021 Jul; 39(7):2439-2446. PubMed ID: 33079250
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy.
Geboers B; Meijer D; Counter W; Blazevski A; Thompson J; Doan P; Gondoputro W; Katelaris A; Haynes AM; Delprado W; O'Neill G; Yuen C; Vis AN; van Leeuwen PJ; Ho B; Liu V; Lee J; Donswijk ML; Oprea-Lager D; Scheltema MJ; Emmett L; Stricker PD
BJU Int; 2024 Apr; 133 Suppl 4():14-22. PubMed ID: 37858931
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic Performance of Prostate-specific Membrane Antigen Positron Emission Tomography-targeted biopsy for Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis.
Kawada T; Yanagisawa T; Rajwa P; Sari Motlagh R; Mostafaei H; Quhal F; Laukhtina E; Aydh A; König F; Pallauf M; Pradere B; Ceci F; Baltzer PAT; Hacker M; Rasul S; Karakiewicz PI; Araki M; Nasu Y; Shariat SF
Eur Urol Oncol; 2022 Aug; 5(4):390-400. PubMed ID: 35715320
[TBL] [Abstract][Full Text] [Related]
9. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Active Surveillance for Prostate Cancer Trial (PASPoRT).
Heetman JG; Lavalaye J; Polm PD; Soeterik TFW; Wever L; Paulino Pereira LJ; van der Hoeven EJRJ; van Melick HHE; van den Bergh RCN
Eur Urol Oncol; 2024 Apr; 7(2):204-210. PubMed ID: 37296065
[TBL] [Abstract][Full Text] [Related]
10. A Prospective Comparison of
Anttinen M; Ettala O; Malaspina S; Jambor I; Sandell M; Kajander S; Rinta-Kiikka I; Schildt J; Saukko E; Rautio P; Timonen KL; Matikainen T; Noponen T; Saunavaara J; Löyttyniemi E; Taimen P; Kemppainen J; Dean PB; Blanco Sequeiros R; Aronen HJ; Seppänen M; Boström PJ
Eur Urol Oncol; 2021 Aug; 4(4):635-644. PubMed ID: 32675047
[TBL] [Abstract][Full Text] [Related]
11. Establishment and prospective validation of an SUV
Jiao J; Kang F; Zhang J; Quan Z; Wen W; Zhao X; Ma S; Wu P; Yang F; Guo W; Yang X; Yuan J; Shi Y; Wang J; Qin W
Theranostics; 2021; 11(17):8396-8411. PubMed ID: 34373749
[No Abstract] [Full Text] [Related]
12. Fluorine-18-labelled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography or Magnetic Resonance Imaging to Diagnose and Localise Prostate Cancer. A Prospective Single-arm Paired Comparison (PEDAL).
Wong LM; Sutherland T; Perry E; Tran V; Spelman T; Corcoran N; Lawrentschuk N; Woo H; Lenaghan D; Buchan N; Bax K; Symons J; Saeed Goolam A; Chalasani V; Hegarty J; Thomas L; Christov A; Ng M; Khanani H; Lee SF; Taubman K; Tarlinton L
Eur Urol Oncol; 2024 Jan; ():. PubMed ID: 38281891
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study.
Lenis AT; Pooli A; Lec PM; Sadun TY; Johnson DC; Lebacle C; Fendler WP; Eiber M; Czernin J; Reiter RE; Calais J
Eur Urol Oncol; 2022 Oct; 5(5):544-552. PubMed ID: 32958451
[TBL] [Abstract][Full Text] [Related]
14. Determining the diagnostic value of PSMA-PET/CT imaging in patients with persistent high prostate specific antigen levels and negative prostate biopsies.
Bodar Y; Koene B; Meijer D; van Leeuwen PJ; Nadorp S; Donswijk ML; Hendrikse NH; Oprea-Lager DE; Vis AN
Urol Oncol; 2022 Feb; 40(2):58.e1-58.e7. PubMed ID: 34404590
[TBL] [Abstract][Full Text] [Related]
15.
Zhang LL; Li WC; Xu Z; Jiang N; Zang SM; Xu LW; Huang WB; Wang F; Sun HB
Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):483-492. PubMed ID: 32734457
[TBL] [Abstract][Full Text] [Related]
16. Prospective analysis of clinically significant prostate cancer detection with [
Bodar YJL; Zwezerijnen BGJC; van der Voorn PJ; Jansen BHE; Smit RS; Kol SQ; Meijer D; de Bie K; Yaqub M; Windhorst BAD; Hendrikse HNH; Vis AN; Oprea-Lager DE
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1731-1742. PubMed ID: 34725727
[TBL] [Abstract][Full Text] [Related]
17. Multiparametric MRI and
Privé BM; Israël B; Janssen MJR; van der Leest MMG; de Rooij M; van Ipenburg JA; Jonker M; Peters SMB; de Groot M; Zámecnik P; Hoepping A; Bomers JG; Gotthardt M; Sedelaar JPM; Barentsz JO; van Oort IM; Nagarajah J
Radiology; 2024 May; 311(2):e231879. PubMed ID: 38771185
[TBL] [Abstract][Full Text] [Related]
18. Targeted prostate biopsy: 68Ga-PSMA PET/CT vs. mpMRI in the diagnosis of prostate cancer.
Pepe P; Pepe L; Tamburo M; Marletta G; Pennisi M; Fraggetta F
Arch Ital Urol Androl; 2022 Sep; 94(3):274-277. PubMed ID: 36165469
[TBL] [Abstract][Full Text] [Related]
19. Detection Rate of
Pepe P; Pepe L; Cosentino S; Ippolito M; Pennisi M; Fraggetta F
Anticancer Res; 2022 Jun; 42(6):3011-3015. PubMed ID: 35641295
[TBL] [Abstract][Full Text] [Related]
20.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]